ReviewJournal of neuro-oncology2025
Diffuse hemispheric glioma, H3 G34-mutant: defining the clinical picture through a single institution case series and literature analysis.
Review in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrated high-resolution copy number and histomolecular analysis of diffuse hemispheric glioma, H3 G34-mutant reveals universal TP53 abnormalities.Brain pathology (Zurich, Switzerland) · 2026Article
- Article
- Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-Mutant: An International Multi-institutional Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Metabolic dependencies and neural progenitor dysregulation: driving forces in paediatric high-grade glioma development.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiffuse hemispheric glioma, H3 G34-mutant (DHG, H3 G34) is an uncommon new tumor type defined in the World Health Organization 2021 classification. DHG, H3 G34 primarily affects children and young adults. There is paucity of knowledge regarding its demographic and prognostic factors. We present an institutional case series and a comprehensive literature review to better determine factors contributing to overall survival.
methodsWe included an institutional case series (n = 6) and comprehensively reviewed previously published individual cases of DHG, H3 G34 through January 2025. A total of 514 individual cases of DHG, H3 G34 were identified and utilized for analyses (n = 257 with individual level survival data). We performed survival analysis using the Kaplan-Meier method and Cox regression.
resultsMedian age of the cohort was 16 years (range: 1-66 years). Median OS was 21 months. OS was improved with gross total resection compared to subtotal resection and biopsy only (Log-rank p < 0.001). Patients with primary tumor location in the right hemisphere had longer OS relative to other tumor locations (Log-rank p < 0.001). Patients with H3 p.G35V (G34V) mutations as opposed to p.G35R mutations had shorter OS (Log-rank p = 0.01). There was no difference in survival outcomes by patient age, MGMT promoter methylation status, the presence of TP53/ATRX/PDGFRA mutations or contrast enhancement.
conclusionsWe present the largest combined data set of patients with DHG, H3 G34 to date and describe in greater clarity the prognostic factors which impact survival in this disease. Unlike many primary brain tumors including glioblastoma and tumors in adolescents and young adults, survival does not appear to be significantly impacted by age.
Indexed as
Identifiers
40402198What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.